Procalcitonin

Figure 1: Immature Calcitonin
A 3D cartoon of procalcitonin's daughter compound, calcitonin
Preview warning: Page using Template:Infobox diagnostic with unknown parameter "Macromolecule Content"

Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, the latter being involved with calcium homeostasis. It arises once preprocalcitonin is cleaved by endopeptidase.[1] It was first identified by Leonard J. Deftos and Bernard A. Roos in the 1970s.[2] It is composed of 116 amino acids and is produced by parafollicular cells (C cells) of the thyroid and by the neuroendocrine cells of the lung and the intestine.

The level of procalcitonin in the blood stream of healthy individuals is below the limit of detection (0.01 μg/L) of clinical assays.[3] The level of procalcitonin rises in a response to a pro-inflammatory stimulus, especially of bacterial origin. It is therefore often classed as an acute phase reactant.[4] The induction period for procalcitonin ranges from 4–12 hours with a half-life spanning anywhere from 22–35 hours.[5] It does not rise significantly with viral or non-infectious inflammations. In the case of viral infections this is due to the fact that one of the cellular responses to a viral infection is to produce interferon gamma, which also inhibits the initial formation of procalcitonin.[6] With the inflammatory cascade and systemic response that a severe infection brings, the blood levels of procalcitonin may rise multiple orders of magnitude with higher values correlating with more severe disease.[7] However, the high procalcitonin levels produced during infections are not followed by a parallel increase in calcitonin or a decrease in serum calcium levels.[8]

  1. ^ "Procalcitonin: Reference Range, Interpretation, Collection and Panels". 2017-03-09. {{cite journal}}: Cite journal requires |journal= (help)
  2. ^ Deftos LJ, Roos BA, Parthemore JG (December 1975). "Calcium and skeletal metabolism". The Western Journal of Medicine. 123 (6): 447–58. PMC 1130411. PMID 1105981.
  3. ^ Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C (December 1994). "Procalcitonin increase after endotoxin injection in normal subjects". The Journal of Clinical Endocrinology and Metabolism. 79 (6): 1605–8. doi:10.1210/jcem.79.6.7989463. PMID 7989463.
  4. ^ Long SS, Pickering LK, Prober CG, eds. (2012). "Bacterial infections in the neonate". Principles and Practice of Pediatric Infectious Diseases (4th ed.). Elsevier. ISBN 978-1437727029.
  5. ^ Reinhart K, Karzai W, Meisner M (September 2000). "Procalcitonin as a marker of the systemic inflammatory response to infection". Intensive Care Medicine. 26 (9): 1193–200. doi:10.1007/s001340000624. PMC 7095266. PMID 11089742.
  6. ^ Sandkovsky, Uriel; Kalil, Andre C.; Florescu, Diana F. (2015-06-22). "The use and value of procalcitonin in solid organ transplantation". Clinical Transplantation. 29 (8): 689–696. doi:10.1111/ctr.12568. ISSN 0902-0063. PMID 25996831. S2CID 10673879.
  7. ^ Meisner M (2010). Procalcitonin biochemistry and clinical diagnosis (1st ed.). Bremen: UNI-MED-Verl. ISBN 9783837412413. OCLC 697831954.
  8. ^ Assicot, M.; Bohuon, C.; Gendrel, D.; Raymond, J.; Carsin, H.; Guilbaud, J. (1993-02-27). "High serum procalcitonin concentrations in patients with sepsis and infection". Lancet. 341 (8844): 515–518. doi:10.1016/0140-6736(93)90277-N. ISSN 0140-6736. PMC 7141580. PMID 8094770.